Cargando…
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas.
Patients with previously untreated squamous cell lung carcinomas were evaluated to see if combining the expression of molecular and cellular factors with the most important clinical prognostic factors could improve the diagnostic ability to predict prognosis. For this reason, immunohistochemistry wa...
Autores principales: | Volm, M., Rittgen, W., Drings, P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149928/ https://www.ncbi.nlm.nih.gov/pubmed/9484827 |
Ejemplares similares
-
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
Publicado: (1998) -
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.
por: Volm, M., et al.
Publicado: (1988) -
Selection and Characterization of a DNA Aptamer That Can Discriminate between cJun/cJun and cJun/cFos
por: Walters, Ryan D., et al.
Publicado: (2014) -
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas.
por: Volm, M., et al.
Publicado: (1997) -
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease
por: Zenz, Rainer, et al.
Publicado: (2008)